RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dumping 20M shares and keeping 10M warrants @$3.18 The reason they have audience is they are outspoken, how can a company build an audience when they are mostly in radio silence mode??
They give timeline for every little move while THTX doesn't even announce the submission of protocols! They tried for years to bring analysts on board,sure the RBC start covering the company thanks to the fact he was awarded to do the convertibles and since then he has been the most negative analyst covering the company yet THTX didn't manage to straighten him up. The concord and NBF analysts got a nice cut closing the offering yet NBF comes out with PT at $3 ish and concord didn't even bothered to produce a report supporting the SP.
Result when they should stop chasing analysts and approach the retail investors they stuck to their failing strategy thus falling SP.
Result of this mismanagement of the capital market CYDY's shareholders have been making money and THTX's shareholders have been losing money.
Result the board and management get nice paycheques, bonuses and options and loyal investors are losing money.
Result in the longest run of the biggest bull market while people are making money THTX's shareholders are losing money.
Wino115 wrote: I've lurked on a few CYTO boards to see what holders and bashers say. The current "big event" they are all keyed on is this Covid trial for leronlimab (newly renamed something else like Viryologic) in severe Covid patients. The trial is something like 2-300 with placebo. The bashers point out monoclonal antibodies have a hard time around acute inflammation and are better at chronic inflammation. The bulls just focus on the science from a small trial and some positive clues the doctors working on the trial have said. The interesting thing is the bulls admit the CEO is way too promotional, sells shares, is a bit of a questionable character, but they like the actual science behind a CCR5 inhibitor. That's all they hang their hat on and they ignore the bizarre capital raising with SEC-barred "toxic lenders". So I guess the only lesson we can say is that massive PR and transparency seems to overcome those issues and they have at least presented the science clearly enough that they have believers. But who knows, if the trial comes back that 50% of severe Covid patients were "cured", I guss that puts it in the category of Remdesivir, so not much of an improvement. I'm sure the share will skyrocket on a 50% efficacy though since it would at least bolster the bulls science argument. I'm not sure the real lessons other than they've somehow created an audience despite the horrible governance optics.
Bucknelly21 wrote: I'm curious about the cydy credibility argument, the market seems to trust them yet everyone here says corruption is the root of their company. The more I see things like this the less faith I have in Thtx to be honest. They get credit for everything they do yet we get nothing and we are apparently the squeaky clean company